Landscape Capital Management L.L.C. Invests $503,000 in Charles River Laboratories International, Inc. $CRL

Key Points

• Landscape Capital Management L.L.C. has invested approximately $503,000 in Charles River Laboratories International, Inc. by acquiring 3,345 shares during the first quarter.
• In addition to Landscape Capital, several other large investors have increased their stakes in Charles River Laboratories, indicating strong interest from institutional investors, who now own 98.91% of the company's stock.
• Analysts have given mixed ratings for Charles River Laboratories, with upgrades leading to a new average price target of$175.69, while the company reported better-than-expected earnings of $3.12 per share in its most recent quarter.

Landscape Capital Management L.L.C. bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,345 shares of the medical research company's stock, valued at approximately $503,000.

A number of other large investors have also bought and sold shares of CRL. Kovitz Investment Group Partners LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $217,000. Northern Trust Corp grew its position in shares of Charles River Laboratories International by 13.5% during the fourth quarter. Northern Trust Corp now owns 492,218 shares of the medical research company's stock worth $90,863,000 after purchasing an additional 58,398 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Charles River Laboratories International by 4.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,963 shares of the medical research company's stock valued at $732,000 after buying an additional 152 shares during the last quarter. Wahed Invest LLC raised its stake in Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock worth $244,000 after acquiring an additional 81 shares during the last quarter. Finally, Ariel Investments LLC boosted its holdings in Charles River Laboratories International by 18.9% in the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after buying an additional 169,640 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. JPMorgan Chase & Co. raised their target price on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research report on Wednesday, May 14th. Finally, Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research report on Thursday, May 8th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $175.69.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of CRL stock traded up $2.23 during mid-day trading on Friday, reaching $164.54. The stock had a trading volume of 168,979 shares, compared to its average volume of 1,231,685. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market cap of $8.10 billion, a price-to-earnings ratio of -123.51, a PEG ratio of 5.19 and a beta of 1.47. The business's fifty day moving average is $160.34 and its 200-day moving average is $149.07.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm's quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business earned $2.80 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).